Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?
Would you consider omitting adjuvant radiation in a very elderly patient with a small triple negative breast cancer?
What dose of reirradiation would you consider for locally recurrent breast cancer after mastectomy, excised with positive margins?
Would you recommend post mastectomy radiation for a low grade adenoid cystic carcinoma of the breast resected with negative margins?
Is it appropriate to use bolus with hypofractionated PMRT?
Would you offer partial breast irradiation for a patient who otherwise meets PBI guidelines but has a PTEN mutation?
In a young woman with large invasive breast carcinoma (case: pT3, lobular) s/p skin sparing mastectomy with positive anterior margin, what is the practical role for re-excision with or without PMRT?
Have the 10-year results from UK FAST-Forward presented at ESTRO 2025 impacted your practice with regard to patient selection?
What is an acceptable upper limit for ipsilateral lung V8 Gy when using the Fast Forward regimen with high tangents to cover limited axillary disease?
Given the 10-year outcomes of UK FAST-Forward presented at ESTRO, how have you expanded the use of ultra-hypofractionation in your practice?
